Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH RECOMBINANT DNA ADVISORY COMMITTEE MEMBERS' POTENTIAL CONFLICTS OF INTEREST SHOULD BE PUBLICLY DISCLOSED -- FOUNDATION ON ECONOMIC TRENDS PETITION

Executive Summary

The Foundation on Economic Trends is recommending that members of the NIH Recombinant DNA Advisory Committee (RAC) should publicly disclose "relevant conflicts of interest," in a recent petition to National Institutes of Health Director Bernadine Healy, MD. Currently, committee members submit individual financial information to NIH's Office of DNA Recombinant Activities, but that information is not made public. FOET, which is headed by genetic engineering critic Jeremy Rifkin, alleges that "a proliferation of egregious examples of ethical improprieties committed by NIH personnel in the recent past demonstrates that the applicable statutes and regulations are not sufficient to prevent conflicts of interest and especially the appearance of conflict of interest." The petition specifically cites the recent resignation of James Watson, MD, formerly the head of NIH's center for genome research, whose financial holdings in several biotech firms were questioned prior to his departure. The petition also questions the appointment of former RAC Chairman Gerard McGarrity, MD, as VP-development at Gaithersburg, Md.-based Genetic Therapy Inc., whose activities include research in the recombinant DNA area. McGarrity, who left the committee in January, responded in a May 28 letter to Healy. "When I planned my career change," McGarrity said, "I made every attempt to carry it out in a totally open and honest manner, fully responsive to the spirit and the letter of applicable rules and regulations." The FOET petition was discussed at RAC's June 2 meeting, but the committee did not take a formal position on the conflict of interest issue. The disclosure issue also is addressed in legislation to amend the Federal Advisory Committee Act, sponsored by Sen. Glenn (D-Ohio). The bill, S 2039, would require all committee members to file a confidential statement disclosing their financial interests as prescribed in a guidance issued by the Office of Government Ethics.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel